CLINICAL IMMUNOLOGY
Liver damage in primary biliary cirrhosis and accompanied by primary Sjögren’s syndrome: a retrospective pilot study
Submission date: 2015-09-21
Final revision date: 2016-03-09
Acceptance date: 2016-03-09
Publication date: 2016-07-15
Cent Eur J Immunol 2016;41(2):182-187
KEYWORDS
ABSTRACT
Introduction: Primary biliary cirrhosis (PBC) and primary Sjögren’s syndrome (pSS) have been referred to as “generalized autoimmune epithelitis”. Indeed, the pathogenic mechanisms, clinical features, and optimal therapeutic approaches for them are not yet fully defined.
Material and methods: A retrospective analysis was carried out on clinical data obtained from 302 inpatients newly diagnosed with PBC, pSS, or the coexistence of PBC and SS between May 2011 and December 2014. Forty-two patients with abnormal hepatic function were divided into the PBC group (n = 17), the coexistent group (PBC accompanied by SS, n = 13), and the pSS group (n = 12). Their clinical symptoms, laboratory data, and pathological features were collected and analyzed when they were first diagnosed. The clinical and laboratory data were collected at 0, 1, and 3 months after treatment.
Results: Of the 42 patients with abnormal liver function, 4 were male and 38 were female patients. Compared with the patients in the PBC group, the patients in the other 2 groups were more likely to have an elevated erythrocyte sedimentation rate (ESR) and serum immunoglobulin G (IgG) levels. Abnormal serum immunoglobulin M levels (IgM) were more frequent in the PBC group. Corticosteroids were effective in normalizing elevated liver enzyme levels in patients with SS and in those with coexistent conditions.
Conclusions: This pilot study suggests that patients with PBC, pSS, and PBC/SS coexistence and having liver function abnormality share similar symptoms, but have different pathogenesis and prognosis.
Material and methods: A retrospective analysis was carried out on clinical data obtained from 302 inpatients newly diagnosed with PBC, pSS, or the coexistence of PBC and SS between May 2011 and December 2014. Forty-two patients with abnormal hepatic function were divided into the PBC group (n = 17), the coexistent group (PBC accompanied by SS, n = 13), and the pSS group (n = 12). Their clinical symptoms, laboratory data, and pathological features were collected and analyzed when they were first diagnosed. The clinical and laboratory data were collected at 0, 1, and 3 months after treatment.
Results: Of the 42 patients with abnormal liver function, 4 were male and 38 were female patients. Compared with the patients in the PBC group, the patients in the other 2 groups were more likely to have an elevated erythrocyte sedimentation rate (ESR) and serum immunoglobulin G (IgG) levels. Abnormal serum immunoglobulin M levels (IgM) were more frequent in the PBC group. Corticosteroids were effective in normalizing elevated liver enzyme levels in patients with SS and in those with coexistent conditions.
Conclusions: This pilot study suggests that patients with PBC, pSS, and PBC/SS coexistence and having liver function abnormality share similar symptoms, but have different pathogenesis and prognosis.
REFERENCES (26)
1.
Tsianos EV, Hoofnagle JH, Fox PC, et al. (1990): Sjögren’s syndrome in patients with primary biliary cirrhosis. Hepatology 11: 730-734.
2.
Skopouli FN, Barbatis C, Moutsopoulos HM (1994): Liver involvement in primary Sjögren’s syndrome. Br J Rheumatol 33: 745-748.
3.
Hatzis GS, Fragoulis GE, Karatzaferis A, et al. (2008): Prevalence and longterm course of primary biliary cirrhosis in primary Sjögren’s syndrome. J Rheumatol 35: 2012-2016.
4.
Vitali C, Bombardieri S, Jonsson R, et al. (2002): Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61: 554-558.
5.
Lindor KD, Gershwin ME, Poupon R, et al. (2009): American Association for Study of Liver Diseases. Primary biliary cirrhosis. Hepatology 50: 291-308.
6.
European Association for the Study of the Liver. (2009): EASL Clinical Practice Guidelines: management of cholestatic liver diseases. Hepatology 51: 237-267.
7.
Abraham S, Begum S, Isenberg D (2004): Hepatic manifestations of autoimmune rheumatic diseases. Ann Rheum Dis 63: 123-129.
8.
Kaplan MJ, Ike RW (2002): The liver is a common non-exocrine target in primary Sjogren’s syndrome: a retrospective review. BMC Gastroenterol 2: 21.
9.
Lindgren S, Manthorpe R, Eriksson S (1994): Autoimmune liver disease in patients with primary Sjogren’s syndrome. Hepatology 20: 354-358.
10.
Wong RK, Lim SG, Wee A, et al. (2008): Primary biliary cirrhosis in Singapore: evaluation of demography, prognostic factors and natural course in a multi-ethnic population. J Gastroenterol Hepatol 23: 599-605.
11.
Alarcon-Segovia D, Diaz-Jouanen E, Fishbein E (1973): Features of Sjögren’s syndrome in primary biliary cirrhosis. Ann Intern Med 79: 31-36.
12.
Golding PL, Brown R, Mason AMS, Taylor E (1970): Sicca complex in liver disease. BMJ 4: 340-342.
13.
Crowe JP, Christensen E, Bulter J, et al. (1980): Primary biliary cirrhosis:the prevalence of hyperthyroidism and its relationship to thyroid autoantibodies and sicca syndrome. Gastroenterology 78: 1437-1441.
14.
Matsumoto T, Morizane T, Aoki Y, et al. (2005): Autoimmune hepatitis in primary Sjögren’s syndrome: pathological study of the livers and labial salivary glands in 17 patients with primary Sjögren’s syndrome. Pathol Int 55: 70-76.
15.
You Z, Wang Q, Bian Z, et al. (2012): The immunopathology of liver granulomas in primary biliary cirrhosis. J Autoimmun 39: 216-221.
16.
Lleo A, Selmi C, Invernizzi P, et al. (2009): Apotopes and the biliary specificity of primary biliary cirrhosis. Hepatology 49: 871-879.
17.
Moritoki Y, Lian ZX, Wulff H, et al. (2007): AMA production in primary biliary cirrhosis is promoted by the TLR9 ligand CpG and suppressed by potassium channel blockers. Hepatology 45: 314-322.
18.
Taylor SL, Dean PJ, Riely CA (1994): Primary autoimmune cholangitis: an alternative to antimitochondrial antibody-negative primary biliary cirrhosis. Am J Surg Pathol 18: 91-99.
19.
Mestecky J, Russell MW, Elson CO (1999): Intestinal IgA: novel views on its function in the defence of the largest mucosal surface. Gut 44: 2-5.
20.
Agmon-Levin N, Kopilov R, Selmi C, et al. (2015): Vitamin D in primary biliary cirrhosis, a plausible marker of advanced disease. Immunol Res 61: 141-146.
21.
Smyk DS, Orfanidou T, Invernizzi P, et al. (2013): Vitamin D in autoimmune liver disease. Clin Res Hepatol Gastroenterol 37: 535-545.
22.
Agmon-Levin N, Theodor E, Segal RM, Shoenfeld Y (2013): Vitamin D in systemic and organ-specific autoimmune diseases. Clin Rev Allergy Immunol 45: 256-266.
23.
Baldini C, Delle Sedie A, Luciano N, et al. (2014): Vitamin D in “early” primary Sjögren’s syndrome: does it play a role in influencing disease phenotypes? Rheumatol Int 34: 1159-1164.
24.
Craig WY, Ledue TB, Collins MF, et al. (2006): Serologic associations of anti-cytoplasmic antibodies identified during anti-nuclear antibody testing. Clin Chem Lab Med 44: 1283-1286.
25.
Mackay IR (2011): Autoimmune Hepatitis from From the Clinic to the Diagnostics Laboratory. Lab Med 42: 224-233.
26.
Rhen T, Cidlowski JA (2005): Antiinflammatory action of glucocorticoids new mechanisms for old drugs. N Engl J Med 353: 1711-1723.
| eISSN: | 1644-4124 |
| ISSN: | 1426-3912 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
